AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 13.16 |
Market Cap | 353.71M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.21 |
PE Ratio (ttm) | -63.24 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 13.66 |
Volume | 4,841 |
Avg. Volume (20D) | 227,237 |
Open | 13.55 |
Previous Close | 13.42 |
Day's Range | 13.28 - 13.55 |
52-Week Range | 3.03 - 15.00 |
Beta | undefined |
About ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezip...
Analyst Forecast
According to 3 analyst ratings, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $18, which is an increase of 35.54% from the latest price.
Next Earnings Release
Analysts project revenue of $10.55M, reflecting a 44.26% YoY growth and earnings per share of 0, making a -100.00% decrease YoY.
2 months ago · seekingalpha.com
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call TranscriptEton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Off...